ocugen_4C_LOGO (002).png
UPDATE -- Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2024 Annual Meeting
April 26, 2024 09:05 ET | Ocugen
MALVERN, Pa., April 26, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...
ocugen_4C_LOGO (002).png
Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2024 Annual Meeting
April 26, 2024 06:30 ET | Ocugen
MALVERN, Pa., April 26, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...
Coave Logo.png
eyeDNA Therapeutics to Present 2-year Follow-up Phase I/II Data on its Investigational Gene Therapy HORA-PDE6b for Retinitis Pigmentosa at the ARVO 2024 Annual Meeting
April 25, 2024 06:00 ET | Coave Therapeutics
Paris, France, April 25, 2024 – eyeDNA Therapeutics (‘eyeDNA’), a newly created subsidiary of Coave Therapeutics (‘Coave’), a genetic medicine company focused on developing life-changing therapies,...
Aggreko logo.png
Aggreko To Provide Energy Solutions for the FORMULA 1 CRYPTO.COM MIAMI GRAND PRIX
April 24, 2024 09:01 ET | Aggreko
Through a multi-year partnership, Aggreko will provide power solutions for the FORMULA 1 CRYPTO.COM MIAMI GRAND PRIX, beginning with the 2024 race.
doheny ucla logo.png
Doheny Eye Institute Announces Upcoming Presentations at ARVO 2024 Annual Meeting
April 24, 2024 09:00 ET | Doheny Eye Institute
PASADENA, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- Doheny Eye Institute, one of the nation’s leading vision research institutions, announced that more than 25 of its scientists and...
Verana+logo+horizontal.jpg
Verana Health Announces Launch of Qdata® Thyroid Eye Disease
April 24, 2024 09:00 ET | Verana Health, Inc.
SAN FRANCISCO, April 24, 2024 (GLOBE NEWSWIRE) -- Verana Health®, a digital health company dedicated to revolutionizing patient care and clinical research through real-world data (RWD), today...
22157.jpg
Glaucoma Global Clinical Trials Review 2024: Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End Points Status
April 24, 2024 08:38 ET | Research and Markets
Dublin, April 24, 2024 (GLOBE NEWSWIRE) -- The "Glaucoma - Global Clinical Trials Review, 2024" clinical trials has been added to ResearchAndMarkets.com's offering.The clinical trial report,...
ocugen_4C_LOGO (002).png
Ocugen Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 2 of Phase 1/2 ArMaDa Clinical Trial of OCU410—A Modifier Gene Therapy
April 19, 2024 07:13 ET | Ocugen
MALVERN, Pa., April 19, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene...
New LifeWallet.png
UPDATE: LifeWallet Announces a Comprehensive Settlement with a Group of Affiliated Property & Casualty Insurers 
April 18, 2024 20:42 ET | LifeWallet
LifeWallet Announces a Comprehensive Settlement with a Group of Affiliated Property & Casualty Insurers
Aqua-Tots Swim Schoo
Aqua-Tots Swim School Prepares to Open First Location in Orlando Area
April 18, 2024 07:30 ET | Aqua-Tots Swim Schools
Oviedo, Florida, April 18, 2024 (GLOBE NEWSWIRE) -- Aqua-Tots Swim School, the largest international swim school franchise, is proud to announce that its newest location is coming soon to the...